LIX1L

LIX1L is a putative double-stranded RNA-binding protein that functions as a post-transcriptional regulator coupling RNA metabolism to cell proliferation, metabolic stress responses, and tissue morphogenesis (PMID:26310847, PMID:33746084). It associates with ribosome biogenesis and RNA-handling factors, including nucleolin (NCL), RIOK1, and PABPC4, and binds multiple miRNAs (PMID:26310847). Phosphorylation at Tyr136 by candidate tyrosine kinases including ROS1 is required for LIX1L-driven cell proliferation, and a peptide that reduces pTyr136 inhibits proliferation and induces apoptosis (PMID:26310847). LIX1L acts on miRNA circuits in liver disease: it suppresses miR-191-3p to relieve repression of LRH-1 and activate the bile acid synthesis genes CYP7A1 and CYP8B1 in cholestasis, with its own expression induced by Egr-1 binding the LIX1L promoter (PMID:33746084), and it raises miR-21-3p to suppress FBP1 and enhance glycolysis, proliferation, and invasion in hepatocellular carcinoma (PMID:34221869). Under metabolic stress it is PARylated by PARP1, which stabilizes the protein and enhances its RNA binding, allowing it to bind AU-rich elements in CD36 mRNA and promote hepatic lipid accumulation, inflammation, and fibrosis (PMID:39725340). During TGFβ1-induced EMT it localizes to the nucleolus and interacts with NCL to drive rRNA synthesis, supporting migration, invasion, and therapy resistance in NSCLC (PMID:36478492). Distinct from its RNA roles, LIX1L bridges DCHS1-based cell adhesions to the SEPT9 septin-actin cytoskeleton to organize filamentous actin during cardiac valve development (PMID:35200715).

1. 2015 Medium

   Established LIX1L as an RNA-binding protein with a defined interactome, answering what molecular class it belongs to and which RNA/protein partners it engages.

   Evidence MALDI-TOF/TOF mass spectrometry and RIP-seq in HEK-293 cells

   PMID:26310847

   Open questions at the time

   • Functional consequence of binding individual miRNAs not tested
   • Direct RNA targets versus indirect associations not resolved
   • No structural basis for dsRNA binding
2. 2015 Medium

   Identified Tyr136 phosphorylation as a proliferation-driving modification and candidate kinases, linking LIX1L to a druggable proliferative signal.

   Evidence MS phosphosite mapping and PY136 peptide inhibition in vitro and in vivo tumor models

   PMID:26310847

   Open questions at the time

   • Which of the candidate kinases (ROS1, HCK, ABL1/2, JAK3, LCK, TYRO3) acts physiologically not determined
   • Downstream effectors of pTyr136 unknown
   • How phosphorylation alters RNA binding not addressed
3. 2019 Low

   Placed LIX1L downstream of a lncRNA-miRNA axis (TATDN1/miR-6089), addressing how LIX1L expression is regulated in HCC.

   Evidence Dual-luciferase reporter and siRNA/overexpression in HCC cell lines

   PMID:31378885

   Open questions at the time

   • Luciferase/overexpression only, no endogenous validation
   • Limited mechanistic depth for LIX1L itself
   • In vivo relevance untested
4. 2021 High

   Defined LIX1L as a post-transcriptional controller of bile acid synthesis via miR-191-3p/LRH-1, and identified Egr-1 as its upstream transcriptional inducer in cholestasis.

   Evidence Lix1l knockout mice across cholestasis models, miRNA microarray, AAV-mediated miR-191-3p delivery, and ChIP

   PMID:33746084

   Open questions at the time

   • Mechanism by which LIX1L suppresses miR-191-3p not defined
   • Whether direct RNA binding mediates miR-191-3p suppression unknown
5. 2021 Medium

   Showed LIX1L promotes HCC glycolysis and aggression through miR-21-3p-mediated FBP1 suppression, connecting it to metabolic reprogramming.

   Evidence Knockdown/overexpression in HCC cells, orthotopic mouse model, and miR-21-3p inhibitor rescue

   PMID:34221869

   Open questions at the time

   • How LIX1L upregulates miR-21-3p not established
   • Direct versus indirect regulation unresolved
6. 2022 Medium

   Revealed a non-RNA structural role: LIX1L bridges DCHS1 adhesions to the SEPT9 septin-actin cytoskeleton to organize actin during valve morphogenesis.

   Evidence Biochemical interaction assays with DCHS1 and SEPT9 in mouse and cell culture models

   PMID:35200715

   Open questions at the time

   • Reciprocal co-IP and interaction domain mapping not specified
   • Whether RNA binding is involved in this role unknown
   • Direct versus complex-mediated interaction unresolved
7. 2022 Medium

   Linked LIX1L to ribosome biogenesis by showing nucleolar relocalization and NCL interaction drive rRNA synthesis and EMT/therapy resistance.

   Evidence Immunofluorescence, co-IP with NCL, NCL knockdown, and rRNA synthesis inhibition with functional cell assays in NSCLC

   PMID:36478492

   Open questions at the time

   • Signal triggering nucleolar relocalization beyond TGFβ1 unclear
   • How LIX1L promotes rRNA transcription mechanistically not defined
8. 2024 Medium

   Established PARP1-mediated PARylation as a metabolic-stress switch that stabilizes LIX1L and enhances RNA binding to stabilize CD36 mRNA, tying it to MASH/HCC.

   Evidence PARP1 inhibition/modification assays, CD36 3'UTR/CDS RNA binding assays, and Lix1l knockout MASH/HCC mouse models

   PMID:39725340

   Open questions at the time

   • PARylation site(s) on LIX1L not mapped
   • Whether PARylation governs other RNA targets unknown

• How LIX1L's multiple modes (Tyr136 phosphorylation, PARylation, miRNA regulation, nucleolar rRNA synthesis, cytoskeletal bridging) are integrated within one protein and which is primary remains unresolved.
• No structural model of the dsRNA-binding motif or its target specificity
• Unified mechanism connecting RNA-binding and cytoskeletal functions absent
• Tissue-specific selection among its diverse roles undefined